John Mendelsohn, M.D., past-president of MD Anderson, is the Director of the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy and Gordon Mills, M.D., Ph.D., chair of the Department of Systems Biology at MD Anderson, is co-director.
Dr. Mendelsohn has been a leader in the field of targeted cancer therapy since 1980, creating, with his colleagues, the first reported inhibitor of the product of a tyrosine kinase oncogene – monoclonal antibody C225 against the EGF receptor – which ultimately led to the FDA approval of the drug, renamed cetuximab (Erbitux), in 2004.
Dr. Mills’ extensive experience with rapidly evolving technology used in the discovery of biomarkers and their application in clinical trials and patient care, directing the Kleberg Center for Molecular Markers, and his visionary T9 program (Ten Thousand Tumors, Ten Thousand Tests, Ten Thousand Therapies) that screens the 40+ most commonly mutationally activated genes, will ensure a timely transition from research to clinic. He designed the T9 program to identify and overcome the hurdles to the first phase of “delivering on the promise of personalized molecular medicine.” Indeed, the approaches developed for T9 will drive the first phase of the genetic and molecular analysis in the Institute. He is leveraging the innovation and discovery of the Kleberg Center for Molecular Markers with the refinements necessary for implementation of CLIA-compliant assays, required for clinical decisions.
This approach will allow MD Anderson to lead the country in the rapid and efficient implementation of the next generation of technologies in patient care.
John Mendelsohn, M.D. - Director, Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy
Gordon Mills, M.D., Ph.D. - Co-Director, Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy
Funda Meric-Bernstam, M.D. - Medical Director, Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy
Kenna Shaw, Ph.D. - Executive Director, Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy
Gordon Mills, M.D., Ph.D.
John Mendelsohn, M.D.
Funda Meric-Bernstam, M.D.
Kenna Shaw, Ph.D.
Stanley Hamilton, M.D.
Marshall Hicks, M.D.